Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Does a diagnosis of myelogenous leukemia require 20% marrow myeloblasts, and does <5% marrow myeloblasts represent a remission? The history and ambiguity of arbitrary diagnostic boundaries in the understanding of myelodysplasia.

Literature DB >> 23982763

Does a diagnosis of myelogenous leukemia require 20% marrow myeloblasts, and does <5% marrow myeloblasts represent a remission? The history and ambiguity of arbitrary diagnostic boundaries in the understanding of myelodysplasia.

Abstract

Entities: Disease

Keywords: Classification; Clonal evolution; Leukemic myeloblasts; Myelodysplasia; Myelogenous leukemia; Neoplasia; Refractory anemia

Mesh：

Year: 2013 PMID： 23982763 PMCID： PMC3780644 DOI： 10.1634/theoncologist.2013-0099

Source DB: PubMed Journal: Oncologist ISSN： 1083-7159

× No keyword cloud information.

19 in total

1. Language and the clonal myeloid diseases.

Authors: Marshall A Lichtman
Journal: Blood Date: 2002-01-15 Impact factor: 22.113

2. The stem cell in the pathogenesis and treatment of myelogenous leukemia: a perspective.

Authors: M A Lichtman
Journal: Leukemia Date: 2001-10 Impact factor: 11.528

3. Clonal architecture of secondary acute myeloid leukemia.

Authors: Matthew J Walter; Dong Shen; Li Ding; Jin Shao; Daniel C Koboldt; Ken Chen; David E Larson; Michael D McLellan; David Dooling; Rachel Abbott; Robert Fulton; Vincent Magrini; Heather Schmidt; Joelle Kalicki-Veizer; Michelle O'Laughlin; Xian Fan; Marcus Grillot; Sarah Witowski; Sharon Heath; John L Frater; William Eades; Michael Tomasson; Peter Westervelt; John F DiPersio; Daniel C Link; Elaine R Mardis; Timothy J Ley; Richard K Wilson; Timothy A Graubert
Journal: N Engl J Med Date: 2012-03-14 Impact factor: 91.245

Review 4. Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia.

Authors: Brent L Wood
Journal: Clin Lab Med Date: 2007-09 Impact factor: 1.935

5. Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics.

Authors: U Bacher; W Kern; T Alpermann; S Schnittger; A Kohlmann; H-U Klein; M Dugas; C Haferlach; T Haferlach
Journal: Leukemia Date: 2011-04-15 Impact factor: 11.528

6. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

Authors: Luca Malcovati; Matteo Giovanni Della Porta; Cristiana Pascutto; Rosangela Invernizzi; Marina Boni; Erica Travaglino; Francesco Passamonti; Luca Arcaini; Margherita Maffioli; Paolo Bernasconi; Mario Lazzarino; Mario Cazzola
Journal: J Clin Oncol Date: 2005-09-26 Impact factor: 44.544

7. [Refractory anemia with excess myeloblasts in the bone marrow. Study of 11 cases].

Authors: B Dreyfus; H Rochant; C Sultan; J P Clauvel; J Yvart; A M Chesneau
Journal: Presse Med Date: 1970-02-14 Impact factor: 1.228

8. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes.

Authors: Kiyoyuki Ogata; Yoshifumi Kishikawa; Chikako Satoh; Hideto Tamura; Kazuo Dan; Akio Hayashi
Journal: Blood Date: 2006-03-30 Impact factor: 22.113

9. Preleukemic states. I. Definition and classification. II. Refractory anemia with an excess of myeloblasts in the bone marrow (smoldering acute leukemia).

Authors: B Dreyfus
Journal: Nouv Rev Fr Hematol Blood Cells Date: 1976

Does a diagnosis of myelogenous leukemia require 20% marrow myeloblasts, and does <5% marrow myeloblasts represent a remission? The history and ambiguity of arbitrary diagnostic boundaries in the understanding of myelodysplasia.

1. Language and the clonal myeloid diseases.

2. The stem cell in the pathogenesis and treatment of myelogenous leukemia: a perspective.

3. Clonal architecture of secondary acute myeloid leukemia.

Review 4. Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia.

5. Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics.

6. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

7. [Refractory anemia with excess myeloblasts in the bone marrow. Study of 11 cases].

8. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes.

9. Preleukemic states. I. Definition and classification. II. Refractory anemia with an excess of myeloblasts in the bone marrow (smoldering acute leukemia).

10. Preleukemia: does it exist?

1. Understanding the mutational evolution of clonal cytopenias and oligoblastic myelogenous leukemia ('myelodysplasia').

2. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

Review 3. Genetics of progression from MDS to secondary leukemia.

4. Minimally Deviated Lymphohematopoietic Neoplasms: Nomenclature in the Context of Pathobiology.

5. TP53 and the star-crossed lovers MDS and AML.